The Contrasting Role of Nasopharyngeal Angiotensin Converting Enzyme 2 (*ACE2*) Expression in SARS-CoV-2 Infection: A Cross-Sectional Study of People Tested for COVID-19 in British Columbia

Authors: Aidan M. Nikiforuk[1,4*] (MSc.), Kevin S. Kuchinski[1,2*] (BSc.), David D.W. Twa[2,3*] (PhD), Christine D. Lukac[1] (MPH), Hind Sbihi[1,4] (PhD), C. Andrew Basham[1,4] (MSc.), Christian Steidl[3] (MD), Natalie A. Prystajecky[1,2] (PhD), Agatha N. Jassem[1,2] (PhD), Mel Krajden[1,2] (MD), David M, Patrick[1,4] (MD) and Inna Sekirov[1,2] (PhD).

[*]these authors contributed equally to the work.

[1]British Columbia Centre for Disease Control, Vancouver, V5Z 4R4, British Columbia, Canada
[2]Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, V6T 1Z4, British Columbia, Canada
[3]British Columbia Cancer Research Centre, Vancouver, V5Z 1L3, British Columbia, Canada
[4]School of Population and Public Health, University of British Columbia, Vancouver, V6T 1Z4, British Columbia, Canada

Corresponding Author: Dr. Inna Sekirov MD/ PhD, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada, V5Z 4R4 and Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada, V6T 1Z4.
email: inna.sekirov@bccdc.ca

47   **Summary**

49   *Background*

50   Angiotensin converting enzyme 2 (*ACE2*) serves as the host receptor for SARS-CoV-2,

with a critical role in viral infection. We aim to understand population level variation of

nasopharyngeal *ACE2* expression in people tested for COVID-19 and the relationship between

ACE2 expression and SARS-CoV-2 viral RNA load, while adjusting for expression of the

complementary protease, Transmembrane serine protease 2 (*TMPRSS2),* soluble *ACE2,* age, and

biological sex.

Methods

58   A cross-sectional study of n=424 participants aged 1-104 years referred for COVID-19

testing was performed in British Columbia, Canada. Participants who tested negative or positive

for COVID-19 were matched by age and biological sex. Viral and host gene expression was

measured by quantitative reverse-transcriptase polymerase chain reaction. Bivariate analysis and

multiple linear regression were performed to understand the role of nasopharyngeal *ACE2*

expression in SARS-CoV-2 infection. The *ACE2* gene was targeted to measure expression of

transmembrane and soluble transcripts.

Findings

67   Analysis shows no association between age and nasopharyngeal *ACE2* expression in

those who tested negative for COVID-19 (P=0·092). Mean expression of transmembrane

(P=1·2e-4), soluble *ACE2* (P<0·0001) and *TMPRSS2* (P<0·0001) differed between COVID-19-

negative and -positive groups. In bivariate analysis of COVID-19-positive participants,

expression of transmembrane *ACE2* positively correlated with SARS-CoV-2 RNA viral load

(P<0·0001), expression of soluble *ACE2* negatively correlated (P<0·0001), and no correlation

was found with *TMPRSS2 (P=0·694).* Multivariable analysis showed that the greatest viral RNA

loads were observed in participants with high transmembrane *ACE2* expression (*B*=0·886,

95%CI:[0·596 to 1·18]), while expression of soluble *ACE2* may protect against high viral RNA

load in the upper respiratory tract (*B*= -0·0990, 95%CI:[-0·176 to -0·0224]).

Interpretation

Nasopharyngeal *ACE2* expression plays a dual, contrasting role in SARS-CoV-2

infection of the upper respiratory tract. Transmembrane *ACE2* positively correlates, while

soluble *ACE2* negatively correlates with viral RNA load after adjusting for age, biological sex

and expression of TMPRSS2.

Funding

This project (COV-55) was funded by Genome British Columbia as part of their COVID-

19 rapid response initiative.

Research in Context

Evidence before this study

We conducted a MEDLINE $^{®}$ search using the MeSH topic terms: "angiotensin

converting enzyme 2 expression" and "SARS" and "age", restricting the search to English-

language reports published from January 1st, 2020. The search returned n=98 articles, eighty-

eight of which reported primary research; these were further filtered by the MeSH qualifiers

"epidemiology" and "virology" to provide n=43 articles. Search results were further restricted to

the MeSH headings: age, virus replication, host pathogen interactions, nasal mucosa, RNA viral

load and real-time polymerase chain reaction, which returned n=24 results. We read through the

abstracts of these twenty-four papers and manually selected n=4 for full review. This review

provided evidence that *ACE2* expression is greater in the upper respiratory tract than the lower

respiratory tract, when measured by single-cell RNA sequencing, immunohistochemistry and

high-sensitivity RNA in-situ mapping. In the upper airway, *ACE2* mRNA abundance closely

correlates with protein concentration. A reverse genetics study demonstrated that a variable

SARS-CoV-2 infection gradient occurs in the respiratory tract, with highest viral loads expected

in the upper airway. In several patient cohorts, upper respiratory expression of *ACE2* was

significantly increased in those who smoke, in this analysis multivariable adjustment of age

suggested limited confounding.

Added Value of this study

We measured *ACE2* expression in the context of COVID-19 testing to investigate the role

of nasopharyngeal *ACE2* in SARS-CoV-2 infection. Our findings support previous work: the

strong correlation we observe between nasopharyngeal *ACE2* expression and SARS-CoV-2 load

also suggests an infection gradient across the human airway. Greater viral loads are expected in

tissue with high transmembrane ACE2 expression. No observed relationship between age and

nasopharyngeal *ACE2* in COVID-19-negative participants suggests that upper airway *ACE2*

expression is independent of the RAAS pathway. We are the first to measure endogenous

expression of soluble *ACE2* in the upper airway of people tested for COVID-19 and include this

measure in multivariable analysis. Importantly, nasopharyngeal expression of soluble *ACE2*

negatively correlates with viral RNA load, inferring a protective role at the population level.

Implications of all the available evidence

Considering all available evidence, *ACE2* may play a dual, contrasting role in SARS-

CoV-2 infection of the upper airway. Expression of transmembrane ACE2 positively correlates

with SARS-CoV-2 RNA load, while expression of soluble ACE2 shows a negative association.

Expression of nasopharyngeal ACE2 does not seem to correlate with age, as would be expected

in the lower respiratory tract. Risk factors such as smoking may affect the baseline risk of high

SARS-CoV-2 RNA loads in those infected. Factors associated with endogenous nasopharyngeal

expression of soluble *ACE2* require further investigation.

Introduction

In December 2019, clusters of viral pneumonia were reported in Wuhan, China. A novel

highly pathogenic human coronavirus was isolated and named severe acute respiratory syndrome

coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease (COVID-19).[1] SARS-

CoV-2 utilizes the same host receptor and protease for cell entry as the human coronaviruses

SARS-CoV and HCoV-NL63. The receptor angiotensin converting enzyme 2 (*ACE2*) mediates

cellular entry, while transmembrane serine protease 2 (TMPRSS2) serves as a complementary

host factor.[2,3] In human physiology, *ACE2* has a cardiovascular protective and anti-inflammatory

role, as a constituent of the renin-angiotensin-aldosterone-system (RAAS).[4] Interestingly,

expression of *ACE2* in the nasopharyngeal tract exceeds that in alveolar tissue, explaining

initiation of SARS-CoV-2 infection in the upper respiratory tract.[5] Transcription of *ACE2*

produces at least two dominant mRNA transcripts responsible for translation into soluble and

membrane-bound protein isoforms.[6] Although the transmembrane isoform has been shown to be

crucial for viral entry into host cells, the role of soluble *ACE2* remains uncharacterized, though

some evidence exists that it protects against SARS-CoV-2 infection.[7,8]　Transmembrane serine

protease 2 (*TMPRSS2*) contributes to SARS-CoV-2 cell entry by cleaving the viral spike protein

into a conformational form necessary for membrane fusion.[2] Unlike *ACE2*, *TMPRSS2* expression

occurs more stably across upper airway tissue and alternative enzymes such as cathepsin B/L

may perform its role in viral infection interchangeably.[5] To understand the importance of *ACE2*

expression in SARS-CoV-2 infection, we performed a cross-sectional study of people tested for

COVID-19 in British Columbia, Canada. The study aims to investigate the relationship between

i) nasopharyngeal expression of *ACE2* and age in COVID-19-negative participants, ii)

nasopharyngeal expression of host genes by COVID-19 test result and iii) nasopharyngeal

expression of transmembrane *ACE2* and viral RNA load in those who tested COVID-19-positive

adjusting for age, biological sex, expression of soluble *ACE2* and *TMPRSS2*. Characterizing

expression of nasopharyngeal *ACE2* in a large group of participants tested for COVID-19 will

increase our knowledge of host genes involved in viral infection and may allow for assessment

of baseline risk.

Methods

Study Design and Participants

We performed cross-sectional sampling of people tested for COVID-19 at the British

Columbia Center for Disease Control Public Health Laboratory (BCCDC-PHL) from 24/3/2020-

9/5/2020. At the time of sampling, provincial health guidelines required a clinical indication for

referral of a COVID-19 test.　Inclusion criteria were applied to select study participants whose

diagnostic specimens were: tested centrally at the BCCDC-PHL, collected by nasopharyngeal

swab, the first test administered by provincial health number, suspended in Hologic Aptima™

media, negative for concurrent Influenza A, B or Respiratory syncytia virus infection, stored at -

80°C following RNA extraction and for whom host gene expression was successfully measured

by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). People meeting the

inclusion criteria (n=444), were excluded (n=16) if samples had a SARS-CoV-2 E gene cycle

threshold (Ct) value of >=38 by qRT-PCR. COVID-19-positive cases (n=212) were matched in a

1:1 ratio with those that tested negative for COVID-19 by age and biological sex (Figure S1).

Ethical approval for the study was obtained from the University of British Columbia

human ethics board (H20-01110). Demographic variables of age and biological sex were drawn

from public health laboratory data. Laboratory methods were performed in a College of

American Pathologists accredited laboratory with externally validated qRT-PCR assays. [9–12]

Procedures

Nasopharyngeal samples collected in Hologic Aptima[TM] media were stored at 4°C before

RNA extraction using the Viral RNA isolation kit on the MagMAX-96[TM] platform

(ThermoFisher).[13]

Host and viral gene targets were assayed by qRT-PCR on the Applied Biosystems 7500

Real-Time PCR platform using TaqMan FastVirus 1-step polymerase (ThermoFisher). Total

reaction volumes equaled 20ul, with 5ul of RNA template, 1ul of 20x primer/probe, 5ul Fast

Virus and 9ul of nuclease free water per reaction. Cycling conditions were set to: 50°C for 5

minutes, 95°C for 20 seconds followed by 40 cycles of 95°C for 15 seconds and 60°C for 1

minute. A multiplex qRT-PCR reaction targeting SARS-CoV-2 envelope (E) and host

ribonuclease P (RNaseP) was used to diagnosis acute viral infection by presence of viral RNA.[14]

Expression of RNaseP was used to ensure sample quality and control for sampling variation.[14]

Participants were diagnosed as COVID-19 positive with an E gene Ct value of <38. The E gene

Ct values were transformed to genome equivalents per millilitre by making a 5-fold, 1:10

standard curve of SARS-CoV-2 synthetic RNA- MN908947·3 (Twist Bioscience) (Table S1).

Commercially available primer probe sets were used to amplify the host gene targets

TMPRSS2[12] (Hs00237175_m1) (ThermoFisher) and *ACE2* [10] (Hs01085333_m1,

HS01085340_m1) by multiplex qRT-PCR with a glyceraldehyde 3-phosphate dehydrogenase

(*GAPDH*) control[11] (Hs02758991_g1) (ThermoFisher). Relative gene expression was calculated

between *TMPRSS2*, *ACE2* and *GAPDH* using the $2^{-\Delta\Delta Ct}$ method.[15] Transmembrane *ACE2* was

defined from the Hs01085333_m1 (ThermoFisher) gene target, which exon spans the

transmembrane domain. Soluble *ACE2* was defined as absolute relative expression between the

Hs01085333_m1 (ThermoFisher) and HS01085340_m1 (ThermoFisher) gene targets (Figure

S3). The HS01085340_m1 target, does not include the transmembrane domain and is positioned

between two motifs essential for SARS-CoV receptor binding (Figure S3).

Statistical Analysis

De-identified data reporting participant COVID-19 test result, site of sample collection,

type of collection media, accessioning laboratory, age and biological sex was accessed from

public health laboratory records. Matching of COVID-19-positive people, who met the described

inclusion, exclusion criteria, to COVID-19-negative participants by age and biological sex in a

1:1 ratio was performed by a nearest neighbor algorithm (n=424).[16] Bivariate analysis was

performed between: age, biological sex, viral RNA load, *TMPRSS2*, soluble or transmembrane

ACE2, and COVID-19 test result. The balance of covariates between test groups was examined

post matching.

The relationship between age and nasopharyngeal expression of transmembrane *ACE2*

was examined in COVID-19-negative participants over the age of 18 by both linear regression

and categorization of age into 9-year intervals. Differences in *ACE2* expression by age category

were tested by analysis of variance.

Differences in mean expression of host genes by COVID-19 diagnosis was further

examined by Levene's test for equal variance and a two-tailed, t-test assuming non-equal

variance.[17] Correlation between host gene expression and viral RNA load was analyzed by

simple linear regression. Multivariable analysis was performed by multiple linear regression,

variable importance was assessed by the partial f-test.[18] Collinearity was examined by the

variable inflation factor with a cut-off of 10.[19] The common cause criterion was applied to

control for measured confounding, effect modification was incorporated when found statistically

significant.[20] All analysis was performed in RStudio version 1.2.5042 using the packages: car,

ggsci, tidyverse, dataexplorer, ggpubr, lmtest, publish, forcats, matchit, tableone and effects. [21]

Role of the Funding Source and Data Stewards

The funder and data stewards played no role in the study design, analysis or interpretation

of the results. As such, interpretation of the results does not reflect the views of the funding

organization or data stewards. The study was performed as research at the University of British

Columbia and British Columbia Centre for Disease Control.

Results

The analytic dataset contains an age- and biological sex-matched sample of n=424 participants tested for COVID-19 in British Columbia from 24/3/2020-9/5/2020 (Figure S1). Participant characteristics are shown in Table 1. The mean age of n=212 COVID-19-positive participants was 61·6, 47·6% were biologically male. In n=212 COVID-19-negative participants, the mean age was 62·1, 48·6% were biologically male. Bivariate analysis between the examined covariates and diagnosis (COVID-19-negative or -positive) shows balance of age (P=0·83) and biological sex (P=0·92) between groups. Viral RNA (E gene Ct) was only detected in COVID-19 positive participants, with an average Ct value of 28·2. Relative expression of transmembrane *ACE2*, soluble *ACE2*, and *TMPRSS2* statistically differed by COVID-19 test result (Table 1).

Table 1: Structure and Characteristics of Analytic Data Stratified by COVID-19 Test Result (n=424).

Variable Name	Level	Total (n)	Negative	Positive	Chi X^2	T-Test
	..	424	212	212	..	..
	..		..	..	..	..
Age (mean [SD])	..	424	62.2 [24.3]	61.7 [23.5]	..	0.83
Sex (n [%])	..	..	..	..	0.92	..
	Male	204	103 [48.6]	101 [47.6]	..	..
	Female	220	109 [51.4]	111 [52.4]	..	..
E Gene Ct (mean [SD])	..	424	..	28.2 [7.18]	..	..
	..	..	..	..	..	..
Transmembrane ACE2 (mean [SD])	..	424	(0.00) [1.08]	(-0.609) [1.90]	..	1.2e-4
Soluble ACE2 (mean [SD])	..	424	(0.00) [0.625]	(-0.898) [1.47]	..	<0.0001
TMPRSS2 Total (mean [SD])	..	424	(0.00) [0.797]	(-1.35) [1.60]	..	<0.0001

Participants who tested negative or positive by COVID-19 were matched by age and biological sex, balance was checked between groups post matching by chi X^2 or t-test (α=0·05). Relative gene expression of ACE2 and TMPRSS2 was normalized to the negative group by the $2^{-\Delta\Delta Ct}$ method. [15]

Relationship between ACE2 expression and age in COVID-19-negative participants

No relationship was found between nasopharyngeal *ACE2* expression and age in COVID-19 negative participants between 19 and 98 years of age with age as a continuous variable by

linear regression (P=0·076). This finding was reproduced when age was categorized into nine-

year intervals (P=0·092) (Figure 1).

Figure 1: Relationship between age and nasopharyngeal transmembrane *ACE2* expression in COVID-19-

negative participants. Boxplots of transmembrane *ACE2* expression by nine-year age categories in COVID-19-

negative participants between the ages of 19 and 98 (n=198); boxes represent the Q1-Q3 interquartile range,

whiskers represent 1.5x the Q1 or Q3 and horizontal lines the median transmembrane ACE2 expression by age

category. Nine-year categories were selected to optimize the distribution of observations between groups.

Participants who tested negative younger than 19 or older than 98 were excluded based on n<10 observations per

age group. No difference was detected in mean transmembrane *ACE2* expression among age categories (ANOVA,

P=0·092).

Nasopharyngeal expression of ACE2 and TMPRSS2 by COVID-19 test result

Bivariate analysis showed a significant mean difference in transmembrane, soluble *ACE2*

and *TMPRSS2* expression between COVID-19-negative and -positive participants (Figure 2).

These differences were further examined to detect non-equal variance for all host gene targets by

COVID-19 test result. Assuming non-equal variance, mean expression differed for

transmembrane *ACE2* (P=1·2e-4), soluble *ACE2* (P<0·0001) and *TMPRSS2* (P<0·0001) between

those testing COVID-19-negative or -positive (Figure 2). Expression of all three host genes was

lower in COVID-19-positive participants.

Figure 2: Relative nasopharyngeal gene expression of targeted host genes by COVID-19 test result. Gene

expression is portrayed in kernel density plots stratified by COVID-19 test result. Probability densities of relative

host gene expression are shown by positive (red, transmembrane *ACE2*; blue, soluble *ACE2*; yellow, *TMPRSS2*) and

negative COVID-19 test results (grey). Levene's test was used to detect non-equal variance in gene expression for

all host targets between COVID-19-negative and -positive participants. A two-tailed, t-test was used to examine

mean difference in host gene expression by COVID-19 test result assuming unequal variance: transmembrane *ACE2*

(P=1·2e-4), soluble *ACE2* (P<0·0001) and *TMPRSS2* (P<0·0001).

Association between host gene expression and viral RNA load in COVID-19-positive

participants

Correlations between each host gene and viral RNA load were examined by simple linear

regression. Nasopharyngeal expression of transmembrane *ACE2* positively correlated with viral

RNA (P<0·0001). Expression of soluble *ACE2* negatively correlated with viral RNA

(P<0·0001). No correlation was found between *TMPRSS2* expression and viral RNA (P=0·69)

(Figure S2). Multiple linear regression estimated that a one-unit change in transmembrane *ACE2*

expression increases viral RNA load by 0·886 Log_{10} GE/mL (95%CI: 0·596 to 1·18) adjusting

for age, biological sex, expression of soluble *ACE2* and *TMPRSS2* (Table 2). No collinearity was

detected between covariates. Biological sex could have been dropped from the model as evident

from comparison between nested models (P=0·76), but was kept for validity. A partial f-test

indicated effect modification between transmembrane and soluble *ACE2* expression (P=0·010)

(Table 2). No effect modification was observed between transmembrane expression of *ACE2* and

TMPRSS2 (P=0·23). High expression of soluble *ACE2* decreases viral RNA load (*B*= -0·0990,

95%CI: [-0·176 to -0·0224]) (Table 2). The association between transmembrane *ACE2*

expression and viral RNA in nasopharyngeal tissue differs by the concomitant level of soluble

ACE2 expressed (Figure 3). Effect modification was visualized by categorizing soluble *ACE2* by

the relative mean expression +/- 2 standard deviations of all study participants (Low= -2·86,

Mean= -0·444, High= 1·98, SD=2·43) (Figure 3).

Table 2: Unadjusted, Adjusted and Effect Modification Linear Regression Models of SARS-CoV-2 Viral RNA Load

Variables	Unadjusted, B(95%CI)	Adjusted, B(95%CI)	Effect Modification, B(95%CI)
Intercept [a]	5.44 (5.12 to 5.77)	2.55 (1.71 to 3.40)	2.48 (1.65 to 3.31)
Transmembrane ACE2 Expression [b]	0.493 (0.329 to 0.656)	0.886 (0.596 to 1.18)	0.624 (0.274 to 0.975)
Soluble ACE2 Expression [c]	--	-0.243 (-0.494 to 0.00834)	-0.484 (-0.794 to - 0.174)
TMPRSS2 Expression [d]	--	-0.873 (-1.21 to -0.533)	-0.713 (-1.07 to -0.336)
Age [e]	--	0.0276 (0.0162 to 0.0389)	0.0259 (0.0146 to 0.0372)
Biological Sex [f]	--	0.0778 (-0.424 to 0.579)	0.0735 (-0.422 to 0.569)
Transmembrane ACE2* Soluble ACE2 Expression [g]	--	--	-0.0990 (-0.176 to -0.0224)

Regression of SARS-CoV-2 viral RNA load by Transmembrane *ACE2*, Soluble *ACE2* and *TMPRSS2* Expression, Age and Biological Sex.

[a] Viral RNA load in females, measured by Log_{10} viral genome equivalents per millilitre (Log_{10} GE/mL) targeting the SARS-CoV-2 *E* gene.

[b] Transmembrane *ACE2* Expression ($2^{-\Delta\Delta Ct}$) in the nasopharyngeal epithelium of SARS-CoV-2 positive participants.

[c] Soluble *ACE2* expression ($2^{-\Delta\Delta Ct}$) in the nasopharyngeal epithelium of SARS-CoV-2 positive participants.

[d] *TMPRSS2* expression ($2^{-\Delta\Delta Ct}$) in the nasopharyngeal epithelium of SARS-CoV-2 positive participants.

[e] Age, measured in years.

[f] Biological sex, effect of being male.

[g] Effect modification term, the effect of transmembrane *ACE2* expression on viral RNA load differs by expression of soluble *ACE2*.

Figure 3: The association between transmembrane *ACE2* expression and SARS-CoV-2 RNA load in

nasopharyngeal tissue differs by the amount of soluble *ACE2* expression. Soluble *ACE2* expression was

categorized into low, mean and high levels to demonstrate the relationship. The low category (grey) represents

soluble *ACE2* expression two standard deviations below the mean expression. The mean category (orange) codes for

the mean soluble *ACE2* expression, zero standard deviations. The high category (blue) indicates soluble *ACE2*

expression two standard deviations above mean expression. Shaded areas represent 95% confidence intervals, solid

lines represent *B* coefficients from multiple linear regression.

Discussion

In the described study, we measured nasopharyngeal *ACE2* and *TMPRRS2* relative gene

expression by qRT-PCR in a cross-sectional sample of n=424 participants tested for COVID-19

in British Columbia. Analysis was performed to understand: the relationship between *ACE2*

expression and age in COVID-19-negative participants, differences in host gene expression

between COVID-19-negative and -positive participants and the role of *ACE2* in SARS-CoV-2

infection in those who tested positive for COVID-19.

Among participants tested negative for COVID-19, we found no relationship between

nasopharyngeal *ACE2* expression and age, in a group of adults between 19-98 years of age. This

result, agrees with findings from other efforts to characterize nasopharyngeal *ACE2* expression at

the population level. Bunyavanich et al. reported a difference in *ACE2* expression levels between

children younger than ten years old and young adults from eighteen to twenty-four years old. [22]

No difference was evident between young adults, and adults twenty-five or more years in age. [22]

Lack of a relationship between nasopharyngeal *ACE2* expression and progressive aging suggests

that expression of *ACE2* in the upper airway does not correlate with expression of *ACE2* in the

RAAS. The physiological importance of *ACE2* in the RAAS suggests that its expression would

increase in response to age as older people have higher prevalence of cardiovascular disease or

similar comorbidities (i.e. diabetes). [23] If nasopharyngeal expression of *ACE2* occurs

independently of the RAAS pathway, future studies should ascertain what factors if any regulate

expression of soluble *ACE2* in nasopharyngeal tissue and variation of *ACE2* expression in

COVID-19-negative people over time. Some populations, such as young children, may have

differential levels of nasopharyngeal *ACE2* expression which protect against SARS-CoV-2 viral

infection.[22,24]

Participants who tested positive for COVID-19 were matched to those who tested

negative by age and biological sex to estimate the direct relationship between host gene

expression and SARS-CoV-2 test result. This analysis demonstrated that mean expression of

transmembrane, soluble *ACE2* and *TMPRSS2* decreased in COVID-19-positive participants,

while variation increased. Unfortunately, the limitation of reverse-causality in cross-sectional

study design prevents us from understanding whether the presence of SARS-CoV-2 in positive

samples affects host gene expression or host gene expression puts people at risk of viral

infection. However, if we make the plausible assumption that at least a single round of viral

replication must occur in order for qRT-PCR to generate a positive test result, it suggests that the

observed variation in host gene expression of participants who test positive for COVID-19

results from viral replication.[25] Numerous studies have demonstrated that coronavirus

replication disrupts cellular transcription, as resources required by the cell to produce mRNA are

instead sequestered by virus to replicate its genome. [26] Reduced transcription of *ACE2* by

SARS-CoV, but not HCoV-NL63, in an *in vitro* model of Vero E6 cell infection was previously

suggested as a pathological mechanism.[3] Putative SARS-CoV-2 disruption of *ACE2* expression

could partially explain the apparent association between hypertension, diabetes, and severe

COVID-19.[27] Answering these questions; however, requires a longitudinal study design to test

the temporal effect of SARS-CoV-2 replication on the expression of *ACE2* and other implicated

host genes.

The sample was then restricted to participants who tested positive for COVID-19 to

investigate the association between nasopharyngeal *ACE2* expression and SARS-CoV-2 RNA

load. Bivariate and multivariable analysis both suggest that *ACE2* plays a dual, contrasting role

in SARS-CoV-2 infection. Transmembrane *ACE2* positively correlates with viral RNA load,

while soluble *ACE2* may limit viral infection by reducing viral RNA load. Interestingly, effect

modification was observed between transmembrane and soluble *ACE2* implicating that the

proportion between these molecules may have more importance than absolute expression of

either individually. For example, between two people with similar above-average

nasopharyngeal transmembrane *ACE2* expression, we would expect a higher viral RNA load in

the one with lower soluble *ACE2* expression. Though we are not equipped to characterize the

mechanism by which soluble *ACE2* plays a protective role in SARS-CoV-2 infection,

identification of this effect at the population level warrants further investigation of the

underlying mechanism. Previous work has postulated that soluble *ACE2* restricts SARS-

CoV/SARS-CoV-2 infection by acting as a decoy substrate.[28] In a study of virus-*ACE2* dynamics

in engineered human tissue, instead of binding to transmembrane *ACE2*, virus particles bound to

soluble *ACE2* and were unable to infect susceptible cells.[28] Moreover, recombinant soluble

ACE2 was recently administered to a COVID-19 patient requiring ventilation.[8] In the case report,

administration of soluble *ACE2* decreased viral RNA load in the patient's plasma, tracheal

aspirate and nasopharyngeal specimens. Additionally, soluble *ACE2* did not interfere with

production of IgG and assumed its cardiovascular protective role in the RAAS.[8]

Soluble *ACE2* may also influence the usage of Neuropilin-1 as a co-receptor or

alternative receptor for SARS-CoV-2. Function of Neuropilin-1 for cell entry and infectivity may

depend upon high SARS-CoV-2 viral load; therefore, expression of soluble *ACE2* may limit

SARS-CoV-2 tropism. [29]

We acknowledge that the described study has several limitations. In our sample, the age

distribution possesses a left skew which prevents us from examining the relationship between

age and nasopharyngeal expression of *ACE2* in participants younger than 18 years of age. The

difference in mean host gene expression observed between participants who tested negative or

positive for COVID-19 cannot be resolved in a cross-sectional study design due to reverse

causality. We attempted to control for immunological gene regulation by excluding people with

endemic respiratory co-infections from Influenza A/B or Respiratory syncytia virus. We describe

associations between transmembrane, soluble *ACE2* and SARS-CoV-2 RNA load which suggest

the dual, contrasting role of *ACE2* in viral infection. However, we cannot provide evidence of the

mechanism responsible for this association. Additionally, the measure of viral RNA load over-

approximates infectious viral titre and viral RNA may be isolated in the absence of infectious

virus.[30]

In conclusion, we have characterized nasopharyngeal *ACE2* expression in a sample of

people tested for COVID-19. Analysis shows no relationship between age and nasopharyngeal

ACE2 expression in COVID-19-negative participants 19-98 years old. Expression of

nasopharyngeal *ACE2* and *TMPRSS2* differs between COVID-19-positive and –negative groups.

The role of nasopharyngeal *ACE2* in SARS-CoV-2 infection of the upper-airway may be

differentiated by gene isoform expression; transmembrane *ACE2* positively correlates with viral

RNA load, while soluble *ACE2* shows a negative association. Nasopharyngeal expression of

ACE2 possesses a dual, contrasting role in SARS-CoV-2 infection at the population level.

Contributors

AMN, DDWT, KSK, NAP, ANJ, MK, DMP, and IS conceived, designed, and obtained funding

for the project. AMN wrote the manuscript, editing was provided by Karen Chu. AMN, DDWT

and KSK performed the experiments. CDL and HS obtained and cleaned laboratory data. AMN,

KSK, DDWT, CAB, CDL, and HS analyzed the data under the direction of CS, NAP, ANJ, MK,

DMP and IS. All authors interpreted the data, edited the manuscript and provided their approval

to publish.

Declaration of Interests

The authors have no conflicts of interest to declare.

Acknowledgments

We would like to acknowledge the work of all our clinical colleagues at the British

Columbia Centre for Disease Control and across the globe in responding to the COVID-19

pandemic. This work would not have been possible without funding from Genome British

Columbia. We would like to thank Michael Donoghue for managing this multi-stakeholder

project and Karen Chu for assisting as a medical copy editor.

References

1   Zhu N, Zhang D, Wang W, *et al.* A Novel Coronavirus from Patients with Pneumonia in
China, 2019. *N Engl J Med* 2020; **382**: 727–33.

2   Hoffmann M, Kleine-Weber H, Schroeder S, *et al.* SARS-CoV-2 Cell Entry Depends on
ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;
181: 271-280.e8.

3   Glowacka I, Bertram S, Herzog P, *et al.* Differential Downregulation of ACE2 by the
Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human
Coronavirus NL63. *J Virol* 2010; **84**: 1198–205.

4   South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular
consequences. *Am J Physiol Circ Physiol* 2020; **318**: H1084–90.

5   Sungnak W, Huang N, Bécavin C, *et al.* SARS-CoV-2 entry factors are highly expressed
in nasal epithelial cells together with innate immune genes. *Nat Med* 2020; **26**: 681–7.

6   Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of
ACE 2, a novel homologue of angiotensin converting enzyme. *FEBS Lett* 2002; **532**: 107–
10.

7   Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of

SARS-CoV-2 by full-length human ACE2. *Science (80-)* 2020; **367**: 1444–8.

8 Zoufaly A, Poglitsch M, Aberle JH, *et al.* Human recombinant soluble ACE2 in severe

COVID-19. *Lancet Respir Med* 2020; published online Sept. DOI:10.1016/S2213-

2600(20)30418-5.

9 Corman VM, Landt O, Kaiser M, *et al.* Detection of 2019 novel coronavirus (2019-nCoV)

by real-time RT-PCR. *Eurosurveillance* 2020; **25**. DOI:10.2807/1560-

7917.ES.2020.25.3.2000045.

10 Messmann R, Dietl A, Wagner S, *et al.* Alterations of the renin angiotensin system in

human end-stage heart failure before and after mechanical cardiac unloading by LVAD

support. *Mol Cell Biochem* 2020; **472**: 79–94.

11 Kitajima T, Okita Y, Kawamura M, *et al.* The relationship between preoperative T helper

cytokines in the ileal mucosa and the pathogenesis of pouchitis. *BMC Gastroenterol* 2020;

20: 277.

12 Shirato K, Kawase M, Matsuyama S. Wild-type human coronaviruses prefer cell-surface

TMPRSS2 to endosomal cathepsins for cell entry. *Virology* 2018; **517**: 9–15.

13 Hologic. Instructions for Using the Aptima Swab Specimen Collection Kit for Patient-

Collected Specimens. 2020.

14 LeBlanc JJ, Gubbay JB, Li Y, *et al.* Real-time PCR-based SARS-CoV-2 detection in

Canadian laboratories. *J Clin Virol* 2020; **128**: 104433.

15 Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time

Quantitative PCR and the 2−ΔΔCT Method. *Methods* 2001; **25**: 402–8.

16 Ho DE, Imai K, King G, Stuart EA. MatchIt : Nonparametric Preprocessing for Parametric

Causal Inference. *J Stat Softw* 2011; **42**. DOI:10.18637/jss.v042.i08.

17 Gastwirth JL, Gel YR, Miao W. The Impact of Levene's Test of Equality of Variances on

Statistical Theory and Practice. *Stat Sci* 2009; **24**: 343–60.

18 Jamshidian M, Jennrich RI, Liu W. A study of partial F tests for multiple linear regression

models. *Comput Stat Data Anal* 2007; **51**: 6269–84.

19 Fox J, Monette G. Generalized Collinearity Diagnostics. *J Am Stat Assoc* 1992; **87**: 178.

20 VanderWeele TJ. Principles of confounder selection. *Eur J Epidemiol* 2019; **34**: 211–9.

21 Rstudio Team. RStudio. 2019.

22 Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of Angiotensin-Converting

496 Enzyme 2 in Children and Adults. *JAMA* 2020; published online May 20.

497 DOI:10.1001/jama.2020.8707.

498 23 Ni W, Yang X, Yang D, *et al.* Role of angiotensin-converting enzyme 2 (ACE2) in

499 COVID-19. *Crit Care* 2020; **24**: 422.

500 24 Dong Y, Mo X, Hu Y, *et al.* Epidemiology of COVID-19 Among Children in China.

501 *Pediatrics* 2020; **145**: e20200702.

502 25 Bar-On YM, Flamholz A, Phillips R, Milo R. SARS-CoV-2 (COVID-19) by the numbers.

503 *Elife* 2020; **9**. DOI:10.7554/eLife.57309.

504 26 Nakagawa K, Lokugamage KG, Makino S. Viral and Cellular mRNA Translation in

505 Coronavirus-Infected Cells. 2016: 165–92.

506 27 Obukhov AG, Stevens BR, Prasad R, *et al.* SARS-CoV-2 Infections and ACE2: Clinical

507 Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes.

508 *Diabetes* 2020; **69**: 1875–86.

509 28 Monteil V, Kwon H, Prado P, *et al.* Inhibition of SARS-CoV-2 Infections in Engineered

510 Human Tissues Using Clinical-Grade Soluble Human ACE2. *Cell* 2020; **181**: 905-913.e7.

511 29 Cantuti-Castelvetri L, Ojha R, Pedro LD, *et al.* Neuropilin-1 facilitates SARS-CoV-2 cell

512 entry and infectivity. *Science (80-)* 2020; : eabd2985.

513 30 Bullard J, Dust K, Funk D, *et al.* Predicting Infectious Severe Acute Respiratory

514 Syndrome Coronavirus 2 From Diagnostic Samples. *Clin Infect Dis* 2020; published

515 online May 22. DOI:10.1093/cid/ciaa638.

524 **Supplementary Material**

Study Participants

Figure S1: Inclusion, exclusion criteria applied to all people tested for COVID-19 in British

Columbia from 24/3/2020-9/5/2020 to select study participants (analytic data). Specimens from people

tested for COVID-19 with the following criteria were included (white box): tested at the BCCDC-PHL,

specimen was collected by nasopharyngeal swab, test was the primary test by provincial health number,

specimen was suspended in Hologic Aptima™ media and stored at -80°C following testing, negative for

Influenza A, B or Respiratory syncytia virus infection and possessing host gene expression data. Those

with a COVID-19-positive diagnosis, were further restricted by excluding (grey box) SARS-CoV-2 E gene

Ct values of > 38 by qRT-PCR (n=212), and matched in a 1:1 ratio with COVID-19-negative people

(n=212) by age and biological sex (bold text).

Figure S2: Correlation between host gene expression in COVID-19-positive participants and SARS-CoV-2

RNA load. The level of transmembrane *ACE2* (red), soluble *ACE2* (blue) and *TMPRSS2* (black) expression in positive cases of COVID-19 and its relationship with SARS-CoV-2 RNA is shown in Log_{10} genome equivalents per millilitre (GE/mL). Host gene expression was measured by quantitative real-time PCR and normalized to expression of the housekeeping gene GAPDH by the ($2^{-\Delta\Delta Ct}$) method. Soluble *ACE2* was defined as absolute relative expression between the Hs01085333_m1 (ThermoFisher) and HS01085340_m1 (ThermoFisher) gene targets (Figure S3).

548 Simple linear regression was used estimate correlations, the reported P values are for the *B*eta-coefficients of host
549 gene expression.
550
551 **Table S1: Serial Dilution of SARS-CoV-2 RNA for Generation of a Standard Curve by Quantitative Real-**
552 **Time Polymerase Chain Reaction.**

Log_{10} Dilution	10^0	10^1	10^2	10^3	10^4
~GE/mL$^{\tau}$	1	10	100	1000	10,000
R1	36.1	32.6	28.9	25.9	22.8
R2	35.8	31.9	28.8	25.8	22.8
R3	34.8	32.3	28.8	25.8	22.8
R4	35.6	31.7	28.8	25.7	22.8
R5	34.5	31.9	28.6	25.7	22.3
R6	34.0	32.1	28.7	25.5	22.7
R7	34.4	31.9	28.6	25.6	22.8
R8	34.1	31.4	28.8	25.6	22.8
R9	34.7	31.4	28.7	25.6	22.9

553 a 5-fold, 1:10 serial dilution of SARS-CoV-2 synthetic RNA was performed over nine independent replicates (n=9)
554 to measure a standard curve by quantitative real-time PCR targeting the viral E gene.
555 $^{\tau}$ a simple linear regression model was fit to n=9 replicates of the SARS-CoV-2 RNA standard curve: GE/mL=b_0 +
556 $b_1 x_1$. Where, Genome Equivalents per millilitre (GE/mL) = 34.5 -1.27ln(x) and R^2= 0.999.
557

Homo sapiens angiotensin I converting enzyme 2 (ACE2), transcript variant 2, mRNA NCBI Reference Sequence: NM_021804.3

```
5' 1 ggcactcata catacactct ggcaatgagg acactgagct cgcttctgaa atttgacaag
    61 ataaccacta aaatctcttt gaattctatg ttgttgtgat cccatggcta cagaggatca
   121 ggagttgaca tagatactct ttggatttca taccatgtgg aggctttctt acttccacgt
   181 gaccttgact gagtttttgaa tagcgcccaa cccaagttca aaggctgata agagagaaaa
   241 tctcatgagg aggtttttagt ctagggaaag tcattcagtg gatgtgatct tggctcacag
   301 gggacgatgt caagctcttc ctggctcctt ctcagccttg ttgctgtaac tgctgctcag
   361 tccaccattg aggaacaggc caagacattt ttg gacaagt ttaaccacga agccgaagac
   421 ctgttctat c aaagttcact tgcttcttgg aattataaca ccaatattac tgaagagaat
   481 gtccaaaaca tgaataatgc tggggacaaa tggtctgcct ttttaaagga acagtccaca
   541 cttgcccaa a tgtatcca ct acaagaaatt cagaatctca cagtcaagct tcagctgcag
   601 gctcttcagc aaaatgggtc ttcagtgctc tcagaagaca agagcaaacg gttgaacaca
   661 attctaaata caatgagcac catctacagt actggaaaag tttgtaaccc agataatcca
   721 caagaatgct tattacttga accaggtttg aatgaaataa tggcaaacag tttagactac
   781 aatgagaggc tctgggcttg ggaaagctgg agatctgagg tcggcaagca gctgagccca
   841 ttatatgaag agtatgtggt cttgaaaaat gagatggcaa gagcaaatca ttatgaggac
   901 tatgggggatt attggagagg agactatgaa gtaaatgggg tagatggcta tgactacagc
   961 cgcgggccagt tgattgaaga tgtggaacat accttttgaag agattaaaacc attata tgaa
  1021 catcttcatg cctatgtgag ggcaaagttg atgaatgcct atccttccta tatcagtcca
  1081 attggatgcc tccctgctca tttgcttggt gatatgtg gg gtagattttg gacaaatctg
  1141 tactctttga cagttccctt tggacagaaa ccaaacatag atgttactga tgcaatggtg
  1201 gaccaggcct gggatgcaca gagaatattc aaggaggccg agaagttctt tgtatctgtt
  1261 ggtcttccta atatgactca aggattctgg gaaaattcca tgctaacgga cccaggaaat
  1321 gttcagaaag cagtctgcca tcccacagct tgggacctgg ggaagggcga cttcagg atc
  1381 cttatgtgca caaaggtgac aatggacgac ttcctgacag ctcatcatga gatggggcat
  1441 atccagtatg atatggcata tgctgcacaa cctttctgc taagaaatgg agctaatgaa
  1501 ggattccatg aagctgttgg ggaaatcatg tcactttctg cagccacacc taagcattta
  1561 aaatccattg tcttctgtc acccgatttt caagaagaca atgaaacaga aataaacttc
  1621 ctgctcaaac aagcactcac gattgttggg actctgccat ttacttacat gttagagaag
  1681 tggaggtgga tggtctttaa aggggaaatt cccaaagacc agtgatgaa aaagtggtgg
  1741 gagatgaagc gagagatagt tggggtggtg gaacctgtgc cccatgatga aacatactgt
  1801 gaccccgcat ctctgttcca tgtttctaat gattactcat tcattcgata ttacacaagg
  1861 acccttttacc aattccagtt tcaagaagca ctttgtcaag cagctaaaca tgaaggccct
  1921 ctgcacaaat gtgacatctc aaactctaca gaagctggac agaaactgtt caatatgctg
  1981 aggcttgaa aatcagaacc ctggaccecta gcattggaaa atgttgtagg agcaaagaac
  2041 atgaatgtaa ggccactgct caactacttt gagcccttat ttacctggct gaaagaccag
  2101 aacaagaatt cttttgtggg atggagtacc gactggagtc catatgcaga ccaaagcatc
  2161 aaagtgagga taagcctaaa atcagctctt ggagataaag catatgaatg gaacgacaat
  2221 gaaatgtacc tgttccgatc atctgttgca tatgctatga ggcagtactt tttaaaagta
  2281 aaaaatcaga tgattctttt tggggaggag gatgtgcgag tggctaaattt gaaaccaaga
  2341 atctcctta atttctttgt cactgcacct aaaaatgtgt ctgatatcat tcctagaact
  2401 gaagttgaaa aggccatcag gatgtcccgg agccgtatca atgatgcttt ccgtctgaat
  2461 gacaacagcc t agagtttct ggggatacag ccaacacttg gacctcctaa ccagccccct
  2521 gtttccatat ggctgattgt ttttggagtt gtgatgggag tgatagtggt tggcattgtc
  2581 atcctgatct tcactgggat cagagatcgg aagaagaaaa ataaagcaag aagtggagaa
  2641 aatcctatg cctccatcga tattagcaaa ggagaaaata atccaggatt ccaaaacact
  2701 gatgatgttc agacctcctt ttagaaaaat ctatgttttt cctcttgagg tgattttgtt
  2761 gtatgtaaat gttaatttca tggtatagaa aatataagat gataaagata tcattaaatg
  2821 tcaaaactat gactctgttc agaaaaaaaa ttgtccaaag acaacatggc caaggagaga
  2881 gcatcttcat tgacattgct ttcagtattt atttctgtct ctggatttga cttctgttct
  2941 gtttcttaat aaggattttg tattagagta tattagggaa agtgtgtatt tggtctcaca
  3001 ggctgttcag ggataatctca aatgtaaatg tctgttgaat ttctgaagtt gaaaacaagg
  3061 atatatcatt ggagcaagtg ttggatcttg tatggaatat ggatggatca cttgtaagga
  3121 cagtgcctgg gaactggtgt agctgcaagg attgagaatg gcatgcatta gctcactttc
  3181 atttaatcca ttgtcaagga tgacatgctt tcttcacagt aactcagttc aagtactatg
  3241 gtgatttgcc tacagtgatg tttggaatcg atcatgcttt cttcaaggtg acaggtctaa
  3301 agagagaaga atccagggaa caggtagagg acattgcttt ttcacttcca aggtgcttga
  3361 tcaacatctc cctgacaaca caaaactaga gccaggggcc tccgtgaact cccagagcat
  3421 gcctgataga aactcatttc tactgttctc taactgtgga gtgaatggaa attccaactg
  3481 tatgttcacc ctctgaagtg ggtacccagt ctcttaaatc ttttgtattt gctcacagtg
  3541 tttgagcagt gctgagcaca aagcagacac tcaataaatg ctagatttac acactc 3'
```

Legend:
- Transmembrane Domain
- SARS-CoV Binding Domain
- ACE-2 HS01085333_m1 3'
- https://www.thermofisher.com/order/genome-database/?pearUXVerSuffix=pearUX2&elcanoForm=true#!/ge/assays/ge_all/?keyword=HS01085333_m1
- ACE-2 HS01085340_m1 5'
- https://www.thermofisher.com/order/genome-database/?pearUXVerSuffix=pearUX2&elcanoForm=true#!/ge/assays/ge_all/?keyword=HS01085340_m1

560 **Figure S3: Nasopharyngeal expression of *ACE2* was determined by two quantitative real-time polymerase**

561 **chain reaction targets, one target (yellow) exon spans the *ACE2* transmembrane domain.** The other does not

562 include the transmembrane domain (pink) and lays nested between two motifs known to interact with the SARS-

563 CoV receptor binding domain (blue). The measure of soluble *ACE2* represents normalized expression of the pink to

564 yellow target, or the proportion of non-transmembrane *ACE2* to transmembrane *ACE2*.